Gilead Sciences, Inc. $GILD Shares Sold by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 832,461 shares of the biopharmaceutical company’s stock after selling 30,056 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Gilead Sciences were worth $124,359,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of GILD. BlackRock Inc. purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth about $15,393,785,000. Legal & General Group Plc bought a new position in shares of Gilead Sciences in the 2nd quarter worth about $1,316,606,000. Deutsche Bank AG bought a new position in shares of Gilead Sciences in the 2nd quarter worth about $918,387,000. Jupiter Topco LLC purchased a new position in Gilead Sciences during the 2nd quarter valued at about $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Gilead Sciences during the 2nd quarter valued at about $398,905,000. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several research reports. Scotiabank boosted their price objective on shares of Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 30th. Morgan Stanley upped their price objective on shares of Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Finally, Argus set a $190.00 target price on shares of Gilead Sciences in a report on Thursday. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $171.07.

Gilead Sciences Trading Down 1.0%

NASDAQ GILD opened at $167.95 on Friday. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $176.58. The stock has a market cap of $208.31 billion, a P/E ratio of -53.15 and a beta of 0.35. The stock’s fifty day moving average price is $154.76 and its 200-day moving average price is $141.66. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company’s revenue was up 6.8% on a year-over-year basis. During the same period last year, the company earned $2.47 earnings per share. As a group, equities analysts forecast that Gilead Sciences, Inc. will post -0.98 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is -103.80%.

Key Headlines Impacting Gilead Sciences

Here are a few of the latest headlines about GILD:

• Positive Sentiment: Gilead’s HIV business is highlighted as a growth driver: Yeztugo sales are gaining momentum, Biktarvy remains a market leader, and the company has an expanding pipeline. Article: Can Gilead Sciences’ HIV Business Fuel Sustainable Long-Term Growth?
• Positive Sentiment: Results from the PURPOSE 5 trial showed twice-yearly injectable lenacapavir had better persistence than daily oral HIV-prevention medicines, with no HIV infections reported in the lenacapavir group. The data could strengthen the commercial outlook for Gilead’s prevention portfolio. Article: Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Neutral Sentiment: Gilead announced a collaboration with TelevisaUnivision and the Latin GRAMMY Awards to promote HIV-prevention awareness. The initiative may support outreach but does not indicate a direct near-term financial impact. Article: Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards

Insider Activity

In other Gilead Sciences news, EVP Keeley Cain Wettan sold 3,399 shares of the firm’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $164.11, for a total transaction of $557,809.89. Following the completion of the sale, the executive vice president directly owned 5,360 shares in the company, valued at approximately $879,629.60. This trade represents a 38.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the insider owned 113,684 shares of the company’s stock, valued at approximately $17,759,714.48. This represents a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 242,709 shares of company stock valued at $39,503,427. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.